Chemotherapy for Metastatic Gastric Cancer Hirofumi Yasui 1 1Division of Gastrointestinal Oncology and Endoscopy, Shizuoka Cancer Center Hospital Keyword: chemotherapy , gastric cancer pp.1015-1022
Published Date 2005/6/25
DOI https://doi.org/10.11477/mf.1403100218
  • Abstract
  • Look Inside
  • Reference

 Chemotherapy for metastatic gastric cancer surely has a survival benefit compared with the best supportive care. In recent decades, some phase III trials have been conducted for metastatic gastric cancer all over the world. However, no chemotherapy regimen has shown a survival benefit due to 5-FU alone, and there is no standard treatment. Recently, not a few anti-tumor agents have been developed, including irinotecan, oral pyrimidines, Taxane, and molecular target agents. Many phase I and II trials conducted in the world have shown activity both as a single agent and as a combination therapy. At present, four phase III trials are underway in Japan. Some of the new regimens are expected to prolong survival and establish a standard treatment for metastatic gastric cancer.

Copyright © 2005, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院